Clinical trial
A Multicenter, Double-Blind, Fixed-Dose, Long-Term Extension Trial of the Safety of Asenapine in Subjects Diagnosed With Bipolar 1 Disorder Who Completed Protocol P05691 (Formerly 041044) (Phase3B, Protocol P05692 [Formerly 041045])
NCT01395992 is registered in ClinicalTrials.gov with Forest Laboratories as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Double-Blind, Fixed-Dose, Long-Term Extension Trial of the Safety of Asenapine in Subjects Diagnosed With Bipolar 1 Disorder Who Completed Protocol P05691 (Formerly 041044) (Phase3B, Protocol P05692 [Formerly 041045])
- Lead sponsor
- Forest Laboratories
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- April 30, 2012
- Completion date
- January 31, 2015
- Enrollment
- 165 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
bipolar i disorder